rasagiline / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 72 Diseases   9 Trials   9 Trials   594 News 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
rasagiline / Generic mfg.
2016-000973-19: Study to verify safety and tolerability of the immediate switch from rasagiline (irreversible MAO-B inhibitor) and safinamide (reversible inhibitor of MAO-B) Studio per verificare la sicurezza e la tollerabilità nel passaggio immediato dal farmaco rasagilina (inibitore MAO-B irreversibile) al farmaco safinamide (inibitore MAO-B reversibile)

Not yet recruiting
4
20
Europe
Xadago, N04BD03, Tablet, XADAGO - 50 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE
IRCCS SAN RAFFAELE PISANA GESTITO DA SAN RAFFAELE ROMA SRL, IRCCS San Raffaele Pisana
Parkinson's Disease Malattia di Parkinson, Parkinson's Disease Malattia di Parkinson, Diseases [C] - Nervous System Diseases [C10]
 
 
2006-004530-33: Rasagiliinin ja essitalopraamin yhteiskäytön turvallisuus

Ongoing
4
12
Europe
Azilect, Cipralex, Azilect, Cipralex, Azilect, Cipralex
Oy Lundbeck
terveet vapaaehtoiset
 
 
2006-005140-89: A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJECTS

Ongoing
4
160
Europe
Rasagiline 1mg tablet, Rasagiline 2 mg tablet, TVP-1012, Selegiline HCl 5 PCH, Nardil, Selegiline HCl 5 PCH, Nardil
TEVA Pharmaceuticals Industries Ltd
This postmarketing Phase I study is performed in healthy volunteers. The IMP rasagiline 1mg is indicated for the treatment of Parkinson\'s Disease (PD).
 
 
2007-007397-28: Evaluation de la tolérance et de l’acceptabilité de la Rasagiline dans le traitement de la maladie de Parkinson au stade précoce

Ongoing
4
240
Europe
Azilect, Sifrol, Azilect, Sifrol, Azilect, Sifrol
Qualissima
Maladie de Parkinson idiopathique au stade précoceMaladie de Parkinson, numéro de classification MedDRA 10061536
 
 
2009-013004-31: Early combined prolonged release ropinirole and rasagiline therapy in newly diagnosed patients with Parkinsons disease. A prospective, randomized, parallel groups, long-term follow-up study including delayed-start design of rasagiline

Ongoing
3
150
Europe
Tablet, Prolonged-release tablet
UNIVERSITA, DEGLI STUDI DI PARMA
Patients with Parkinson, s diesease
 
 
ACTRN12614000355673: Investigating the effect of Rasagiline on freezing of gait in Parkinson’s disease using accelerometry and functional MRI.

Not yet recruiting
2/3
40
 
A/Prof Simon Lewis, Lundbeck Australia
Freezing of gait in Parkinson's disease
 
 
NCT05611372: Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease

Withdrawn
2/3
732
NA
Rasagiline
Second Affiliated Hospital, School of Medicine, Zhejiang University, Beijing Tiantan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Jiangsu Province Nanjing Brain Hospital, The First Affiliated Hospital of Anhui Medical University, Huashan Hospital, Second Affiliated Hospital of Soochow University, Guizhou Medical University, The First Affiliated Hospital of Guangzhou Medical University, West China Hospital, Sir Run Run Shaw Hospital, The Affiliated Hospital of Hangzhou Normal University, The First Affiliated Hospital of Dalian Medical University, Qilu Hospital of Shandong University, Fujian Medical University Union Hospital
REM Sleep Behavior Disorder, Parkinson Disease, Synucleinopathies
12/25
12/26
NCT02789020: Image Parkinson's Disease Progression Study

Completed
2
96
US
Rasagiline, Azilect, MAO-B inhibitor, Placebo, Magnetic Resonance Imaging, MRI, functional Magnetic Resonance Imaging, fMRI, Physical Function Performance Test
University of Florida, National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson's Disease
05/23
05/23
2008-002145-22: Klinische Untersuchung zur Verträglichkeit und Wirksamkeit nach Umstellung von Selegilin auf Rasagilin bei Patienten mit Morbus Parkinson und Schlafstörungen. Prospektive, offene, explorative Studie mit Umstellung von Selegilin auf Rasagilin.

Ongoing
1/2
30
Europe
Rasagilin, Rasagilin (Azilect®), Rasagilin (Azilect®)
NeuroCode AG
Parkinsonpatienten, die bezüglich ihrer motorischen Tagesaktivität optimal eingestellt sind, leiden trotzdem vermehrt unter Tagesmüdigkeit und Schlafstörungen (Chaudhuri, 2002). Es wird angenommen, dass eine Umstellung der Patienten von Selegilin auf Rasagilin zu einer deutlichen klinischen Verbesserung, insbesondere der Schlafproblematik führen wird.
 
 
ChiCTR1800017978: A randomized, open label, single-dose, double-cycle, double-crossover, fasting and feedbioequivalence trial of Rasagiline Mesylate tablets in healthy subjects

Recruiting
1
108
 
T-R ;R-T ;T-R ; R-T
Beijing Shijitan Hospital Capital Medical University; Level of the institution：, Changzhou Siyao Pharmaceuticals Co., Ltd
parkinsonism
 
 
NCT06798519: Relative Bioavailability Study of HNC364 Injectable Suspension

Not yet recruiting
1
30
NA
HNC364 Injectable Suspension, Rasagiline Tablets
Guangzhou Henovcom Bioscience Co. Ltd.
Parkinson's Disease (PD)
05/26
06/26
ChiCTR1800016949: Efficacy assessment and standard treatment of rasagiline in Chinese patients with early Parkinson's disease

Not yet recruiting
N/A
260
 
rasagiline-rasagiline ;placebo-rasagiline
Beijing Hospital; Beijing Hospital, Ministry of Science and Technology, China
Parkinson's disease
 
 
ChiCTR2500099491: Randomized, Open-Label, Single-Dose, Four-Period, Fully Replicated Crossover Bioequivalence Study of Rasagiline Mesylate Tablets in Healthy Subjects Under Fasting and Fed Conditions

Completed
N/A
64
 
1 tablet of the subject formulation orally on an empty stomach in the first cycle, 1 tablet of the reference formulation orally on an empty stomach in the second cycle, 1 tablet of the subject formulation orally on an empty stomach in the third cycle, 1 tablet of the reference formulation orally on an empty stomach in the fourth cycle; 1 tablet of fasting oral reference preparation in the first cycle, 1 tablet of fasting oral test preparation in the second cycle, 1 tablet of fasting oral reference preparation in the third cycle, 1 tablet of fasting oral test preparation in the fourth cycle; In the first cycle, one tablet of oral test preparation was taken after eating a high-fat and high-heat meal, one tablet of oral reference preparation was taken during the second cycle, and one tablet of oral test preparation was taken during the third cycle. , in the fourth cycle, after eating a high-fat and high-heat meal, take 1 tablet of oral reference preparation; In the first cycle, one tablet of oral reference preparation was taken after eating a high-fat and high-heat meal, one tablet of oral test preparation was taken during the second cycle, and one tablet of oral reference preparation was taken during the third cycle. , in the fourth cycle, after eating a high-fat and high-heat meal, take one tablet of oral test preparation
Zhejiang Hospital; Zhejiang Hospital, Suzhong Pharmaceutical Group Co., Ltd.
Parkinson’s disease,PD
 
 
SUCCESS, NCT03994328: An Observational Study on Safinamide, Rasagiline and Other Standard of Care in PD

Completed
N/A
1235
Europe
Zambon SpA, Iqvia Pty Ltd
Parkinson's Disease
12/23
12/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
rasagiline / Generic mfg.
2016-000973-19: Study to verify safety and tolerability of the immediate switch from rasagiline (irreversible MAO-B inhibitor) and safinamide (reversible inhibitor of MAO-B) Studio per verificare la sicurezza e la tollerabilità nel passaggio immediato dal farmaco rasagilina (inibitore MAO-B irreversibile) al farmaco safinamide (inibitore MAO-B reversibile)

Not yet recruiting
4
20
Europe
Xadago, N04BD03, Tablet, XADAGO - 50 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE
IRCCS SAN RAFFAELE PISANA GESTITO DA SAN RAFFAELE ROMA SRL, IRCCS San Raffaele Pisana
Parkinson's Disease Malattia di Parkinson, Parkinson's Disease Malattia di Parkinson, Diseases [C] - Nervous System Diseases [C10]
 
 
2006-004530-33: Rasagiliinin ja essitalopraamin yhteiskäytön turvallisuus

Ongoing
4
12
Europe
Azilect, Cipralex, Azilect, Cipralex, Azilect, Cipralex
Oy Lundbeck
terveet vapaaehtoiset
 
 
2006-005140-89: A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJECTS

Ongoing
4
160
Europe
Rasagiline 1mg tablet, Rasagiline 2 mg tablet, TVP-1012, Selegiline HCl 5 PCH, Nardil, Selegiline HCl 5 PCH, Nardil
TEVA Pharmaceuticals Industries Ltd
This postmarketing Phase I study is performed in healthy volunteers. The IMP rasagiline 1mg is indicated for the treatment of Parkinson\'s Disease (PD).
 
 
2007-007397-28: Evaluation de la tolérance et de l’acceptabilité de la Rasagiline dans le traitement de la maladie de Parkinson au stade précoce

Ongoing
4
240
Europe
Azilect, Sifrol, Azilect, Sifrol, Azilect, Sifrol
Qualissima
Maladie de Parkinson idiopathique au stade précoceMaladie de Parkinson, numéro de classification MedDRA 10061536
 
 
2009-013004-31: Early combined prolonged release ropinirole and rasagiline therapy in newly diagnosed patients with Parkinsons disease. A prospective, randomized, parallel groups, long-term follow-up study including delayed-start design of rasagiline

Ongoing
3
150
Europe
Tablet, Prolonged-release tablet
UNIVERSITA, DEGLI STUDI DI PARMA
Patients with Parkinson, s diesease
 
 
ACTRN12614000355673: Investigating the effect of Rasagiline on freezing of gait in Parkinson’s disease using accelerometry and functional MRI.

Not yet recruiting
2/3
40
 
A/Prof Simon Lewis, Lundbeck Australia
Freezing of gait in Parkinson's disease
 
 
NCT05611372: Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease

Withdrawn
2/3
732
NA
Rasagiline
Second Affiliated Hospital, School of Medicine, Zhejiang University, Beijing Tiantan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Jiangsu Province Nanjing Brain Hospital, The First Affiliated Hospital of Anhui Medical University, Huashan Hospital, Second Affiliated Hospital of Soochow University, Guizhou Medical University, The First Affiliated Hospital of Guangzhou Medical University, West China Hospital, Sir Run Run Shaw Hospital, The Affiliated Hospital of Hangzhou Normal University, The First Affiliated Hospital of Dalian Medical University, Qilu Hospital of Shandong University, Fujian Medical University Union Hospital
REM Sleep Behavior Disorder, Parkinson Disease, Synucleinopathies
12/25
12/26
NCT02789020: Image Parkinson's Disease Progression Study

Completed
2
96
US
Rasagiline, Azilect, MAO-B inhibitor, Placebo, Magnetic Resonance Imaging, MRI, functional Magnetic Resonance Imaging, fMRI, Physical Function Performance Test
University of Florida, National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson's Disease
05/23
05/23
2008-002145-22: Klinische Untersuchung zur Verträglichkeit und Wirksamkeit nach Umstellung von Selegilin auf Rasagilin bei Patienten mit Morbus Parkinson und Schlafstörungen. Prospektive, offene, explorative Studie mit Umstellung von Selegilin auf Rasagilin.

Ongoing
1/2
30
Europe
Rasagilin, Rasagilin (Azilect®), Rasagilin (Azilect®)
NeuroCode AG
Parkinsonpatienten, die bezüglich ihrer motorischen Tagesaktivität optimal eingestellt sind, leiden trotzdem vermehrt unter Tagesmüdigkeit und Schlafstörungen (Chaudhuri, 2002). Es wird angenommen, dass eine Umstellung der Patienten von Selegilin auf Rasagilin zu einer deutlichen klinischen Verbesserung, insbesondere der Schlafproblematik führen wird.
 
 
ChiCTR1800017978: A randomized, open label, single-dose, double-cycle, double-crossover, fasting and feedbioequivalence trial of Rasagiline Mesylate tablets in healthy subjects

Recruiting
1
108
 
T-R ;R-T ;T-R ; R-T
Beijing Shijitan Hospital Capital Medical University; Level of the institution：, Changzhou Siyao Pharmaceuticals Co., Ltd
parkinsonism
 
 
NCT06798519: Relative Bioavailability Study of HNC364 Injectable Suspension

Not yet recruiting
1
30
NA
HNC364 Injectable Suspension, Rasagiline Tablets
Guangzhou Henovcom Bioscience Co. Ltd.
Parkinson's Disease (PD)
05/26
06/26
ChiCTR1800016949: Efficacy assessment and standard treatment of rasagiline in Chinese patients with early Parkinson's disease

Not yet recruiting
N/A
260
 
rasagiline-rasagiline ;placebo-rasagiline
Beijing Hospital; Beijing Hospital, Ministry of Science and Technology, China
Parkinson's disease
 
 
ChiCTR2500099491: Randomized, Open-Label, Single-Dose, Four-Period, Fully Replicated Crossover Bioequivalence Study of Rasagiline Mesylate Tablets in Healthy Subjects Under Fasting and Fed Conditions

Completed
N/A
64
 
1 tablet of the subject formulation orally on an empty stomach in the first cycle, 1 tablet of the reference formulation orally on an empty stomach in the second cycle, 1 tablet of the subject formulation orally on an empty stomach in the third cycle, 1 tablet of the reference formulation orally on an empty stomach in the fourth cycle; 1 tablet of fasting oral reference preparation in the first cycle, 1 tablet of fasting oral test preparation in the second cycle, 1 tablet of fasting oral reference preparation in the third cycle, 1 tablet of fasting oral test preparation in the fourth cycle; In the first cycle, one tablet of oral test preparation was taken after eating a high-fat and high-heat meal, one tablet of oral reference preparation was taken during the second cycle, and one tablet of oral test preparation was taken during the third cycle. , in the fourth cycle, after eating a high-fat and high-heat meal, take 1 tablet of oral reference preparation; In the first cycle, one tablet of oral reference preparation was taken after eating a high-fat and high-heat meal, one tablet of oral test preparation was taken during the second cycle, and one tablet of oral reference preparation was taken during the third cycle. , in the fourth cycle, after eating a high-fat and high-heat meal, take one tablet of oral test preparation
Zhejiang Hospital; Zhejiang Hospital, Suzhong Pharmaceutical Group Co., Ltd.
Parkinson’s disease,PD
 
 
SUCCESS, NCT03994328: An Observational Study on Safinamide, Rasagiline and Other Standard of Care in PD

Completed
N/A
1235
Europe
Zambon SpA, Iqvia Pty Ltd
Parkinson's Disease
12/23
12/23

Download Options